Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...

A critical problem within the standard practice of market analysis is that the methodologies often beg the question: the ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong ...

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Dr. Jared Weiss details the importance of continued research into novel therapies for patients with lung cancer.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, plus ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.